Abstract
Psychostimulant use disorder and schizophrenia have a substantial genetic basis. Evidence from human and animal studies on the involvement of the γ-aminobutyric acid (GABA) system in methamphetamine (METH) use disorder and schizophrenia is mounting. As we tested for the association of the human GABAA receptor gamma 2 subunit gene (GABRG2) with each diagnostic group, we used a case-control design with a set of 178 subjects with METH use disorder, 288 schizophrenics and 288 controls. First, we screened 96 controls and identified six SNPs in GABRG2, three of whom we newly reported. Next, we selected two SNPs, 315C > T and 1128 + 99C > A, as representatives of the linkage disequilibrium blocks for further case-control association analysis. Although no associations were found in either allelic or genotypic frequencies, we detected a haplotypic association in GABRG2 with METH use disorder, but not with schizophrenia. This finding partly replicates a recent case-control study of GABRG2 in METH use disorder, and thus indicates that GABRG2 may be one of the susceptibility genes of METH use disorder.
| Original language | English |
|---|---|
| Pages (from-to) | 89-95 |
| Number of pages | 7 |
| Journal | Pharmacogenomics Journal |
| Volume | 5 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 19-04-2005 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Genetics
- Pharmacology
Cite this
}
Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder. / Nishiyama, T.; Ikeda, M.; Iwata, Nakao; Suzuki, T.; Kitajima, T.; Yamanouchi, Y.; Sekine, Y.; Iyo, M.; Harano, M.; Komiyama, T.; Yamada, M.; Sora, I.; Ujike, H.; Inada, T.; Furukawa, T.; Ozaki, N.
In: Pharmacogenomics Journal, Vol. 5, No. 2, 19.04.2005, p. 89-95.Research output: Contribution to journal › Article
TY - JOUR
T1 - Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder
AU - Nishiyama, T.
AU - Ikeda, M.
AU - Iwata, Nakao
AU - Suzuki, T.
AU - Kitajima, T.
AU - Yamanouchi, Y.
AU - Sekine, Y.
AU - Iyo, M.
AU - Harano, M.
AU - Komiyama, T.
AU - Yamada, M.
AU - Sora, I.
AU - Ujike, H.
AU - Inada, T.
AU - Furukawa, T.
AU - Ozaki, N.
PY - 2005/4/19
Y1 - 2005/4/19
N2 - Psychostimulant use disorder and schizophrenia have a substantial genetic basis. Evidence from human and animal studies on the involvement of the γ-aminobutyric acid (GABA) system in methamphetamine (METH) use disorder and schizophrenia is mounting. As we tested for the association of the human GABAA receptor gamma 2 subunit gene (GABRG2) with each diagnostic group, we used a case-control design with a set of 178 subjects with METH use disorder, 288 schizophrenics and 288 controls. First, we screened 96 controls and identified six SNPs in GABRG2, three of whom we newly reported. Next, we selected two SNPs, 315C > T and 1128 + 99C > A, as representatives of the linkage disequilibrium blocks for further case-control association analysis. Although no associations were found in either allelic or genotypic frequencies, we detected a haplotypic association in GABRG2 with METH use disorder, but not with schizophrenia. This finding partly replicates a recent case-control study of GABRG2 in METH use disorder, and thus indicates that GABRG2 may be one of the susceptibility genes of METH use disorder.
AB - Psychostimulant use disorder and schizophrenia have a substantial genetic basis. Evidence from human and animal studies on the involvement of the γ-aminobutyric acid (GABA) system in methamphetamine (METH) use disorder and schizophrenia is mounting. As we tested for the association of the human GABAA receptor gamma 2 subunit gene (GABRG2) with each diagnostic group, we used a case-control design with a set of 178 subjects with METH use disorder, 288 schizophrenics and 288 controls. First, we screened 96 controls and identified six SNPs in GABRG2, three of whom we newly reported. Next, we selected two SNPs, 315C > T and 1128 + 99C > A, as representatives of the linkage disequilibrium blocks for further case-control association analysis. Although no associations were found in either allelic or genotypic frequencies, we detected a haplotypic association in GABRG2 with METH use disorder, but not with schizophrenia. This finding partly replicates a recent case-control study of GABRG2 in METH use disorder, and thus indicates that GABRG2 may be one of the susceptibility genes of METH use disorder.
UR - http://www.scopus.com/inward/record.url?scp=20144389670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20144389670&partnerID=8YFLogxK
U2 - 10.1038/sj.tpj.6500292
DO - 10.1038/sj.tpj.6500292
M3 - Article
C2 - 15772696
AN - SCOPUS:20144389670
VL - 5
SP - 89
EP - 95
JO - Pharmacogenomics Journal
JF - Pharmacogenomics Journal
SN - 1470-269X
IS - 2
ER -